{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:28:54Z","timestamp":1789504134237,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1124\/dmd.117.076034","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:30:26Z","timestamp":1498782626000},"page":"1035-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes"],"prefix":"10.1016","volume":"45","author":[{"given":"Lei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.076034_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/dmd.117.076034_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0091270010375959","article-title":"Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro\/in vivo correlation","volume":"51","author":"Brainard","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib3","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/AAC.00292-13","article-title":"Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans","volume":"57","author":"Castellino","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.117.076034_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0076-6879(05)00007-8","article-title":"Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases","volume":"400","author":"Court","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.117.076034_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.117.076034_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-3565(24)29222-3","article-title":"Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms","volume":"299","author":"Court","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.076034_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008571-200006000-00009","article-title":"Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms","volume":"10","author":"Court","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.117.076034_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.117.076034_bib9","first-page":"1179","article-title":"Latent Mycobacterium tuberculosis infection","volume":"373","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.117.076034_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002280100268","article-title":"Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine","volume":"57","author":"Giancarlo","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"10.1124\/dmd.117.076034_bib13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076034_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.117.076034_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076034_bib16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.076034_bib17","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/0006-2952(79)90123-0","article-title":"Evidence for the involvement of N-acetyl-p- quinoneimine in acetaminophen metabolism","volume":"28","author":"Miner","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/tx050317i","article-title":"Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity","volume":"19","author":"Mutlib","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.076034_bib19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.1983.tb02256.x","article-title":"Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation","volume":"16","author":"Ochs","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/clpt.1981.94","article-title":"Diazepam interaction with antituberculosis drugs","volume":"29","author":"Ochs","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.076034_bib21","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"10.1124\/dmd.117.076034_bib22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1124\/jpet.104.071803","article-title":"Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro","volume":"311","author":"Polasek","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.076034_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.076034_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/AAC.33.8.1237","article-title":"Pharmacokinetics of rifabutin","volume":"33","author":"Skinner","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.117.076034_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/dmd.32.1.140","article-title":"An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes","volume":"32","author":"Soars","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076034_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","article-title":"Variability in human cytochrome P450 paclitaxel metabolism","volume":"275","author":"Sonnichsen","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.076034_bib27","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry Drug Interaction Studies \u2014 Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Draft Guidance. CDER, Silver Spring, Maryland."},{"key":"10.1124\/dmd.117.076034_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human udp-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076034_bib29","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076034_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000139107","article-title":"Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes","volume":"47","author":"von Moltke","year":"1993","journal-title":"Pharmacology"},{"key":"10.1124\/dmd.117.076034_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bdd.2510140204","article-title":"in vitro by probenecid","volume":"14","author":"von Moltke","year":"1993","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.117.076034_bib32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","article-title":"Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes","volume":"57","author":"Wen","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib33","unstructured":"World Health Organization (WHO). (2010) Guidelines for Treatment of Tuberculosis. 4th ed. WHO Press, Geneva, Switzerland."},{"key":"10.1124\/dmd.117.076034_bib34","unstructured":"World Health Organization (WHO). (2016) Global Tuberculosis Report 2016. WHO Press, Geneva, Switzerland."},{"key":"10.1124\/dmd.117.076034_bib35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/phar.1482","article-title":"Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis","volume":"34","author":"Worley","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.117.076034_bib36","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/bcp.12644","article-title":"Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen","volume":"80","author":"Zhao","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076034_bib37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405400X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562405400X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.076034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:30:26Z","timestamp":1739903426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562405400X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S009095562405400X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.076034","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.076034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}